Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that Concentra... Read More

SAN DIEGO / Jan 30, 2024 / Business Wire / As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common... Read More

CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra... Read More

CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023 , the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated... Read More

CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value. In... Read More

CAMBRIDGE, Mass. , Nov. 7, 2023 /PRNewswire/ -- T heseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on... Read More

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-variant KIT inhibitor candidate for GIST expected in H1 2024 Announces plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications based on dose-dependent reductions in serum tryptase levels in... Read More

Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 Theseus announces new program targeting KIT for patients with early-line GIST; development candidate nomination expected in the H1 2024... Read More

CAMBRIDGE, Mass. , May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in a live Fireside Chat at the Jefferies Healthcare Conference on June 8 th at... Read More

THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both major classes of KIT resistance mutations at exposures consistent with preclinical predictions observed in Predictive Resistance Assay™ Evidence of clinical activity observed in heavily pre-treated patient population at exposures... Read More

THE-630 initial dose escalation data to be presented at investor event on May 25, 2023 , with additional dose escalation data expected in Q4 2023 IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023; development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected by early 2024 $243.6 million of cash, cash equivalents, and marketable securities as of March 31, 2023 , with runway projected into... Read More

Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that... Read More

CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate virtually in the following upcoming investor conferences: Event: 22 nd Annual... Read More

CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.... Read More

THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND submission expected in Q4 2023 for THE-349 in EGFR-mutant NSCLC BCR-ABL prioritized as third development program for patients with CML and Ph+ ALL; development candidate nomination expected by early 2024 Current cash runway projected... Read More

CAMBRIDGE, Mass. , Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will participate virtually in the SVB Securities Global Biopharma Conference, taking place February... Read More

Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor THE-349 expected in Q4 2023 Introducing BCR-ABL as target for third program, in development for CML and Ph+ ALL; development candidate nomination expected by early 2024 CAMBRIDGE, Mass. , Jan. 5, 2023 /PRNewswire/ -- Theseus... Read More